COVID vaccine: some waste is normal – but here's how it is being kept to a minimum

With reports emerging of vaccine wastage across the world, medical supply chain experts explain why that's to be expected.

Liz Breen, Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Reader in Health Service Operations, University of Bradford • conversation
Jan. 11, 2021 ~8 min

covid-19 supply-chains astrazeneca pfizerbiontech-vaccine vaccine-distribution vaccine-roll-out covid-vaccine

Delaying second COVID-19 vaccine doses will make supplies last longer but comes with risks

With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it's better to give one dose to more people and give a second when the supply is better.

Sanjay Mishra, Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University • conversation
Jan. 11, 2021 ~11 min

 covid-19  coronavirus  immune-system  pandemic  t-cells  antibodies  sars-cov-2  moderna  astrazeneca  pfizerbiontech-vaccine

How many people need to get a COVID-19 vaccine in order to stop the coronavirus?

Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.

Pedro Mendes, Professor of Cell Biology, University of Connecticut • conversation
Jan. 5, 2021 ~8 min

covid-19 coronavirus transmission vaccines immunity population herd-immunity viruses pfizer moderna astrazeneca

The top scientific breakthrough for 2020 was understanding SARS-CoV-2 and how it causes COVID-19 – and then developing multiple vaccines

The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.

David Pride, Associate Director of Microbiology, University of California San Diego • conversation
Dec. 17, 2020 ~11 min

 innovation  genome  covid-19  immune-system  pandemic  vaccines  sars-cov-2  remdesivir  drug-development  monoclonal-antibodies  astrazeneca  pfizerbiontech-vaccine  moderna-vaccine  pfizer-vaccine

What are emergency use authorizations, and do they guarantee that a vaccine or drug is safe?

The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?

Jeremy Greene, Professor of Medicine, Johns Hopkins University • conversation
Dec. 3, 2020 ~10 min

covid-19 coronavirus fda vaccines coronavirus-vaccine pfizer aids moderna emergency-use-authorization astrazeneca covid-19-vaccines eua fda-drug-approval-process

Oxford-AstraZeneca vaccine is cheaper than Pfizer's and Moderna's and doesn't require supercold temperature

There is now a third vaccine that prevents COVID-19 infections. It isn't quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.

Sanjay Mishra, Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University • conversation
Nov. 24, 2020 ~9 min

 covid-19  immune-system  pandemic  vaccines  sars-cov-2  antibody  university-of-oxford  astrazeneca  covid-19-vaccines  pfizerbiontech-vaccine  moderna-vaccine  pfizer-vaccine

Why we didn't get a vaccine by Election Day – but why we may get one soon

With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. With some half-dozen vaccines in phase 3 trials, why wasn't one ready before Election Day?

William Petri, Professor of Medicine, University of Virginia • conversation
Nov. 10, 2020 ~9 min

 covid-19  coronavirus  pandemic  rna  vaccines  pfizer  moderna  emergency-use-authorization  astrazeneca

/

1